Università di Modena
Welcome,         Profile    Billing    Logout  
 0 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Niger, Monica
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting
3
200
Europe, US, RoW
Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma
05/26
08/26
PURITY, NCT06037980: CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence

Recruiting
2/3
300
Europe
Gemcitabine, Nab paclitaxel, Abraxane, Cisplatin, Curative Surgery, Capecitabine
Gruppo Oncologico del Nord-Ovest
Biliary Tract Cancer, Cholangiocarcinoma
12/28
01/29
ImmunoXXL, NCT05879328: The Study

Recruiting
N/A
12
Europe
Liver Transplantation
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Hepatocellular Carcinoma
12/24
12/24
Salati, Massimilano
PURITY, NCT06037980: CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence

Recruiting
2/3
300
Europe
Gemcitabine, Nab paclitaxel, Abraxane, Cisplatin, Curative Surgery, Capecitabine
Gruppo Oncologico del Nord-Ovest
Biliary Tract Cancer, Cholangiocarcinoma
12/28
01/29

Download Options